Esketamine
| Evidence Level: L4 | Predicted Indications: 2 |
Table of Contents
Esketamine: From Treatment-Resistant Depression to Agoraphobia
One-Sentence Summary
Esketamine is an NMDA receptor antagonist marketed in the US as Spravato. Its original indication is depression, based on general knowledge, because the Evidence Pack has no license indication text. The TxGNN model predicts it may be effective for agoraphobia, but 0 clinical trials and only 1 general review article currently support this direction, so the prediction is still a research question.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Treatment-resistant depression (general knowledge; the license record has no indication text) |
| Predicted New Indication | Agoraphobia |
| TxGNN Prediction Score | 99.57% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Esketamine is an NMDA receptor antagonist that produces rapid glutamatergic and synaptic plasticity effects. These effects have been studied in treatment-resistant depression and, in smaller exploratory work, in anxiety-spectrum conditions.
The link to agoraphobia is indirect. It is extrapolated from the general anxiety-disorder literature, and there is no agoraphobia-specific mechanism or data. The rationale rests on general knowledge of the drug class, not on evidence specific to this drug and condition.
The TxGNN score of 99.57% is a knowledge-graph computational prediction. It is not clinical evidence and should be treated as a hypothesis-generating signal only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33424664 | 2020 | Review | Frontiers in Psychiatry | Reviews current approved and off-label drug treatments for panic disorder, generalized anxiety disorder and social anxiety disorder. It notes that few novel medications are under investigation for anxiety disorders. The available abstract text does not show agoraphobia-specific esketamine data. |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA211243 | Spravato (Janssen Pharmaceuticals Inc.) | Solution | Not listed in the provided data |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score and one general anxiety-disorder review. There are no registered trials and no agoraphobia-specific data. Drug-level safety and mechanism data are also missing.
The second predicted indication, benign paroxysmal torticollis of infancy, has no supporting evidence and no plausible mechanistic link in the data. It is not recommended for further pursuit.
To proceed, the following is needed:
- The US package insert, with warnings and contraindications, to complete the safety screening. This is a blocking gap.
- Mechanism of action data from DrugBank, to support a mechanistic link to agoraphobia and anxiety-spectrum conditions.
- Agoraphobia-specific or panic disorder clinical evidence for esketamine, from trials or targeted literature.
- Confirmation of the approved indication text for NDA211243.
- A benefit-risk assessment of esketamine’s dissociation and blood pressure effects in an anxiety population.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.